Literature DB >> 6856249

Retinitis pigmentosa. A symposium on terminology and methods of examination.

.   

Abstract

This report represents a summary of opinions expressed at a meeting of specialists interested in retinitis pigmentosa (RP) and allied diseases, at which an attempt was made to define some minimum guidelines for ocular evaluation of these disorders. The term RP would be reserved for a group of hereditary disorders that diffusely involve photoreceptor and pigment epithelial function, and should not be used when a secondary cause is suspected. RP may be classified by genetic type (single cases without known affected relatives should be termed isolated or simplex), by the topography of retinal involvement, and by the severity of disease (to identify subtypes with mild or localized disease). Patients should have at least one comprehensive examination that conforms to basic standards, preferable early in the course of the disease. The visual field examination should use both a small and a large test light. Electroretinographic testing should (1) use a full-field stimulus, and (2) routinely document three independent responses (cone, rod, and mixed cone-rod). Patients should be identifiable for future study or therapeutic trials. They should be counseled about the disease and followed regularly. No specific therapy exists at present for most of these diseases, but optical and night vision aids are available. Sunglasses for outdoor use are recommended until more is known about whether long-term exposure to bright sunlight alters the course of these diseases.

Entities:  

Mesh:

Year:  1983        PMID: 6856249

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  24 in total

1.  The wide field multifocal electroretinogram reveals retinal dysfunction in early retinitis pigmentosa.

Authors:  F M Dolan; S Parks; H Hammer; D Keating
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

2.  Clinical and genetic heterogeneity in retinitis pigmentosa.

Authors:  J Kaplan; D Bonneau; J Frézal; A Munnich; J L Dufier
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

3.  Seeing through their eyes: lived experiences of people with retinitis pigmentosa.

Authors:  M Prem Senthil; J Khadka; K Pesudovs
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

4.  Slowing the degenerative process, long lasting effect of hyperbaric oxygen therapy in retinitis pigmentosa.

Authors:  Enzo Maria Vingolo; Monica Rocco; PierLuigi Grenga; Serena Salvatore; Paolo Pelaia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

5.  Dark- and light-adapted visual evoked cortical potentials in retinitis pigmentosa.

Authors:  S G Jacobson; R W Knighton; R M Levene
Journal:  Doc Ophthalmol       Date:  1985-08-30       Impact factor: 2.379

6.  Autosomal dominant retinitis pigmentosa: a log quotient analysis of the photopic and scotopic b-wave amplitude.

Authors:  H Iijima; D A Martin; J R Heckenlively
Journal:  Br J Ophthalmol       Date:  1989-05       Impact factor: 4.638

Review 7.  Ocular findings in a form of retinitis pigmentosa with a rhodopsin gene defect.

Authors:  E L Berson
Journal:  Trans Am Ophthalmol Soc       Date:  1990

8.  Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome.

Authors:  Mohamed A Genead; Gerald A Fishman
Journal:  Arch Ophthalmol       Date:  2010-09

9.  X-linked dominant cone-rod degeneration: linkage mapping of a new locus for retinitis pigmentosa (RP 15) to Xp22.13-p22.11.

Authors:  R E McGuire; L S Sullivan; S H Blanton; M W Church; J R Heckenlively; S P Daiger
Journal:  Am J Hum Genet       Date:  1995-07       Impact factor: 11.025

10.  Long-term follow-up of a family with dominant X-linked retinitis pigmentosa.

Authors:  D M Wu; H Khanna; P Atmaca-Sonmez; P A Sieving; K Branham; M Othman; A Swaroop; S P Daiger; J R Heckenlively
Journal:  Eye (Lond)       Date:  2009-11-06       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.